The offensive in the United States raises Esteve's sales to 828 million
The multinational company earns 72 million euros net, a slight decrease due to currency exchange, and finishes the new plants in Celrà and China
BarcelonaThe pharmaceutical company Esteve accelerates its scale-up. The multinational headquartered in Barcelona has closed the 2025 fiscal year with net revenues of 828 million euros, a figure that represents an 11% growth (based on gross turnover) compared to the previous year and confirms the solidity of its strategic plan. Although operating profit (ebitda) has soared by 19% to 151 million, net profit has stood at 72 million euros – a slight decrease of 4% – due to the impact of the dollar exchange rate and the absence of extraordinary financial income that marked 2024.
With these figures, CEO Staffan Schüberg reaffirms the firm's horizon: to surpass the 1,000 million turnover barrier in 2027. In this regard, the company's performance is not only explained by internal growth but also by an aggressive "inorganic growth" policy that has involved an accumulated investment of over 500 million euros in the last two years. This capital injection has served to incorporate up to eight new highly specialized products into its pharmaceutical portfolio – mainly in the areas of oncology and endocrinology – and to strengthen its contract development and manufacturing organization (CDMO) division.
The bet on the United States
The great engine of this new stage is the North American market. The year 2025 has been consolidated for Esteve as the year of expansion into the United States with the acquisition of Regis Technologies, an operation that has allowed the Catalan company to enter the development and manufacturing of active ingredients in the world's largest pharmaceutical market. This offensive has continued: last March it purchased the infusion therapies unit from the American company TerSfera.
Currently, the US market and the rest of the world already represent 23% of the company's sales, approaching the weight of the Spanish market (24%), which continues to lose prominence in favor of internationalization.
Profitability and investment
Operating profit (ebitda) has risen to 151 million euros, 19% more in 2024, and has maintained a margin of 18% on net revenue. However, net profit stood at 72 million euros. This slight variation compared to the 75 million in 2024, as explained by Rosa Maria Garcia, financial director, is mainly attributed to the impact of the dollar exchange rate and the absence of financial extraordinary items that inflated last year's results. In fact, she insisted that with a constant exchange rate, net profits would be higher.
In the industrial section, the pharmaceutical company has allocated 104 million euros to CAPEX –investments in fixed assets–, of which 70% has been concentrated in its industrial branch. The bulk of this investment has gone into the construction of the two new plants in Celrà (Gironès) and Shangyu (China), works that are expected to be completed this very 2026 and which are to be key to absorbing the growth forecast for the coming years.
Growth with an ethical certificate
Beyond the numbers, Esteve took advantage of the results presentation to boast about its B Corp certification, obtained during 2025. According to Maria Àngels Valls, Director of People & Communications, the company's objective is to pursue social and environmental impact with the same strength as financial results. The firm currently has more than 2,200 employees of 35 nationalities and presents 50% gender parity in its governance positions.